Minority Health Archive

The Case Of BiDil: A Policy Commentary On Race And Genetics

Carlson, Rick J (2005) The Case Of BiDil: A Policy Commentary On Race And Genetics. Health Affairs, W5. pp. 464-468.

Full text not available from this repository.


The Food and Drug Administration (FDA) approval of BiDil unleashed a vigorous commentary, mostly critical of the decision. The FDA was soon caught between biologists, who see research and clinical utility in using racial classifications, and social scientists (and many politicians), who fear the adversities of greater discrimination. Analyses rarely addressed the practical factors the FDA had to consider in reaching a decision. Much of the literature simply assigned the question to the domain of racial politics, failing to consider the ethics of professional care, the Hippocratic oath, and the marketplace efficiency in moving drugs quickly to those who might most benefit.

Export/Citation:EndNote | BibTeX | Dublin Core | ASCII (Chicago style) | HTML Citation | OpenURL | Reference Manager
Social Networking:

Item Type: Article
Uncontrolled Keywords: BiDil, policy, race, genetics, Food and Drug Administration (FDA), racial classification, discrimination, racial politics
Subjects: Health > Health Equity
Health > Policy
Research > Genetics and Race
Related URLs:
Depositing User: Kismet Loftin-Bell
Date Deposited: 12 Oct 2005
Last Modified: 03 Jun 2011 12:15
Link to this item (URI): http://health-equity.lib.umd.edu/id/eprint/276

Actions (login required)

View Item